A Phase 2/3 interventional study of Bifidobacterium viable pharmaceutics and Berberine Hydrochloride in Prediabetes, sponsored by Xijing Hospital. Withdrawn at 4 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by Xijing Hospital · Phase 2/3, Interventional, and Prevention
The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.
Gut microbiota may play an important role in patients with prediabetes. Berberine, which is usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.
999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.
Browse Prediabetic State studies →Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
Drug: Bifidobacterium viable pharmaceutics
Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
Drug: Berberine Hydrochloride
Change in 2-hour postprandial blood glucose between baseline to week 12
2-hour postprandial blood glucose are measured at baseline and week 12 during a 2 hour-meal test.
Time frame: Baseline and Week 12
Gut microbiome composition
Faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces.
Time frame: Baseline and week 12
Adverse effects
Standardized questionaries regarding gastrointestinal function are filled out at each study visit (0, 4, 8 and 12 weeks after randomization) to detect possible adverse effects of antibiotics. In addition, subjects are given a calendar and informed to write down any symptom or illness during the study period.
Time frame: From baseline to week 12
This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xijing Hospital